Proteomics and polycystic ovary syndrome

Expert Review of Proteomics

Volumn 10, Issue 5, 2013, Pages 435-447

  Insenser, María ^a   Escobar Morreale, Héctor F ^a,b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

adipose tissue; polycystic ovary syndrome; proteomics

Indexed keywords

3 HYDROXYISOBUTYRATE DEHYDROGENASE; ALBUMIN; ALPHA 1B GLYCOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; CATHEPSIN D; CYTOKERATIN 9; DISULFIDEISOMERASE A3; FIBRINOGEN; FIBRINOGEN GAMMA; GLUTATHIONE TRANSFERASE M3; HAPTOGLOBIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN BETA 1; KERATIN TYPE I CYTOSKELETAL 9; LIPOCORTIN 5; OXIDOREDUCTASE; PEROXIREDOXIN 2; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; SEROTRANSFERRIN; SUPEROXIDE DISMUTASE; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG;

ABDOMINAL SUBCUTANEOUS FAT; HUMAN; INTRAABDOMINAL FAT; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME; PROTEOME; PROTEOMICS; TRANSCRIPTOME;

EID: 84886007976     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2013.837665     Document Type: Review

References (75)

1. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J. Clin. Endocrinol. Metab. 84(6), 1897-1899 (1999).
2. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 85(7), 2434-2438 (2000).
3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89(6), 2745-2749 (2004).
4. Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol. Obstet. Invest. 69(4), 274-280 (2010).
5. Azziz R, Carmina E, Dewailly D et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91(11), 4237-4245 (2006).
6. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int. J. Obes. Relat. Metab. Disord. 26(7), 883-896 (2002).
7. Carmina E, Bucchieri S, Esposito A et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J. Clin. Endocrinol. Metab. 92(7), 2500-2505 (2007).
8. Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol. Metab. 18(7), 266-272 (2007).
9. Borruel S, Fernandez-Duran E, Alpañes M et al. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J. Clin. Endocrinol. Metab. 98(3), 1254-1263 (2013).
10. Wickenheisser JK, Nelson-DeGrave VL, McAllister JM. Human ovarian theca cells in culture. Trends Endocrinol. Metab. 17(2), 65-71 (2006).
11. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril. 83(5), 1454-1460 (2005).
12. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J. Clin. Endocrinol. Metab. 90(8), 4650-4658 (2005).
13. Garcia-Romero G, Escobar-Morreale HF. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus. Curr. Diab. Rev. 2(1), 39-49 (2006).
14. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch. Intern. Med. 166(19), 2081-2086 (2006).
15. Wild RA, Carmina E, Diamanti-Kandarakis E et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95(5), 2038-2049 (2010).
16. Kosova G, Urbanek M. Genetics of the polycystic ovary syndrome. Mol. Cell. Endocrinol. 373(1-2), 29-38 (2013).
17. Zawadzki JK DA. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Polycystic ovary Syndrome. Dunaif A, Givens JR, Haseltine FP, Merriam GR (Eds). Blackwell Scientific Publications, Boston, MA, USA, 377-384 (1992).
18. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19(1), 41-47 (2004).
19. Mischak H, Apweiler R, Banks RE et al. Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin. Appl. 1(2), 148-156 (2007).
20. Tuck MK, Chan DW, Chia D et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J. Proteome Res. 8(1), 113-117 (2009).
21. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics. 1(11), 845-867 (2002).
22. Darde VM, Barderas MG, Vivanco F. Depletion of high-abundance proteins in plasma by immunoaffinity subtraction for two-dimensional difference gel electrophoresis analysis. Methods Mol. Biol. 357, 351-364 (2007).
23. Elliott MH, Smith DS, Parker CE, Borchers C. Current trends in quantitative proteomics. J. Mass Spectrom. 44(12), 1637-1660 (2009).
24. Wu WW, Wang G, Baek SJ, Shen RF. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel-or LC-MALDI TOF/TOF. J. Proteome Res. 5(3), 651-658 (2006).
25. Malik R, Dulla K, Nigg EA, Korner R. From proteome lists to biological impact-tools and strategies for the analysis of large MS data sets. Proteomics 10(6), 1270-1283 (2010).
26. Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum. Reprod. Update 19(3), 268-288 (2013).
27. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89(6), 2548-2556 (2004).
28. Fruhbeck G. Overview of adipose tissue and its role in obesity and metabolic disorders. Methods Mol. Biol. 456, 1-22 (2008).
29. Peinado JR, Pardo M, de la Rosa O, Malagon MM. Proteomic characterization of adipose tissue constituents, a necessary step for understanding adipose tissue complexity. Proteomics 12(4-5), 607-620 (2012).
30. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol. Sci. 24(6), 276-283 (2003).
31. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes. Rev. 11(1), 11-18 (2010).
32. Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116(1), 39-48 (2007).
33. Goodpaster BH, Krishnaswami S, Harris TB et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch. Intern. Med. 165(7), 777-783 (2005).
34. Pascot A, Lemieux S, Lemieux I et al. Age-related increase in visceral adipose tissue and body fat and the metabolic risk profile of premenopausal women. Diabetes Care 22(9), 1471-1478 (1999).
35. Corton M, Villuendas G, Botella JI, San Millan JL, Escobar-Morreale HF, Peral B. Improved resolution of the human adipose tissue proteome at alkaline and wide range pH by the addition of hydroxyethyl disulfide. Proteomics 4(2), 438-441 (2004).
36. Insenser M, Montes-Nieto R, Vilarrasa N et al. A nontargeted proteomic approach to the study of visceral and subcutaneous adipose tissue in human obesity. Mol. Cell. Endocrinol. 363(1-2), 10-19 (2012).
37. Ahmed M, Neville MJ, Edelmann MJ, Kessler BM, Karpe F. Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring) 18(1), 27-34 (2009).
38. Salgado-Somoza A, Teijeira-Fernandez E, Fernandez AL, Gonzalez-Juanatey JR, Eiras S. Proteomic analysis of epicardial and subcutaneous adipose tissue reveals differences in proteins involved in oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 299(1), H202-H209 (2010).
39. Roca-Rivada A, Alonso J, Al-Massadi O et al. Secretome analysis of rat adipose tissues shows location-specific roles for each depot type. J. Proteomics 74(7), 1068-1079 (2011).
40. Celis JE, Moreira JM, Cabezon T et al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol. Cell. Proteomics 4(4), 492-522 (2005).
41. Rajesh RV, Heo GN, Park MR et al. Proteomic analysis of bovine omental, subcutaneous and intramuscular preadipocytes during in vitro adipogenic differentiation. Comp. Biochem. Physiol. Part D Genomics Proteomics 5(3), 234-244 (2010).
42. Ma X, Fan L, Meng Y et al. Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Mol. Hum. Reprod. 13(8), 527-535 (2007).
43. Choi DH, Lee WS, Won M et al. The apolipoprotein A-I level is downregulated in the granulosa cells of patients with polycystic ovary syndrome and affects steroidogenesis. J. Proteome Res. 9(9), 4329-4336 (2010).
44. Kim YS, Gu BH, Choi BC et al. Apolipoprotein A-IV as a novel gene associated with polycystic ovary syndrome. Int. J. Mol. Med. 31(3), 707-716 (2013).
45. Dai G, Lu G. Different protein expression patterns associated with polycystic ovary syndrome in human follicular fluid during controlled ovarian hyperstimulation. Reprod. Fertil. Dev. 24(7), 893-904 (2012).
46. Adams J, Franks S, Polson DW et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 2(8469-70), 1375-1379 (1985).
47. Franks S, Mason H, Willis D. Follicular dynamics in the polycystic ovary syndrome. Mol. Cell. Endocrinol. 163(1-2), 49-52 (2000).
48. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum. Reprod. Update 14(4), 367-378 (2008).
49. Fortune JE. Ovarian follicular growth and development in mammals. Biol. Reprod. 50(2), 225-232 (1994).
50. Misiti S, Stigliano A, Borro M et al. Proteomic profiles in hyperandrogenic syndromes. J. En.docrinol. Invest. 33(3), 156-164 (2010).
51. Borro M, Gentile G, Stigliano A, Misiti S, Toscano V, Simmaco M. Proteomic analysis of peripheral T lymphocytes, suitable circulating biosensors of strictly related diseases. Clin. Exp. Immunol. 150(3), 494-501 (2007).
52. Coombs KM. Quantitative proteomics of complex mixtures. Expert Rev. Proteomics 8(5), 659-677 (2011).
53. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18(11), 2071-2077 (1997).
54. Corton M, Botella-Carretero JI, Lopez JA et al. Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. Hum. Reprod. 23(3), 651-661 (2008).
55. Insenser M, Martinez-Garcia MA, Montes R, San-Millan JL, Escobar-Morreale HF. Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation. J. Clin. Endocrinol. Metab. 95(8), 3863-3870 (2010 ).
56. Montes-Nieto R, Insenser M, Martinez-Garcia MA, Escobar-Morreale HF. A nontargeted proteomic study of the influence of androgen excess on human visceral and subcutaneous adipose tissue proteomes. J. Clin. Endocrinol. Metab. 98(3), E576-E585 (2013).
57. Matharoo-Ball B, Hughes C, Lancashire L et al. Characterization of Biomarkers in Polycystic Ovary Syndrome (PCOS) using multiple distinct proteomic platforms. J. Proteome Res. 6(8), 3321-3328 (2007).
58. Zhao S, Qiao J, Li M, Zhang X, Yu J, Li R. Discovery of distinct protein profiles for polycystic ovary syndrome with and without insulin resistance by surface-enhanced laser adsorption/ionization time of flight mass spectrometry. Fertil. Steril. 88(1), 145-151 (2007).
59. Insenser M, Montes-Nieto R, Murri M, Escobar-Morreale HF. Proteomic and metabolomic approaches to the study of polycystic ovary syndrome. Mol. Cell. Endocrinol. 370(1-2), 65-77 (2013).
60. Escobar-Morreale HF. Iron metabolism and the polycystic ovary syndrome. Trends Endocrinol. Metab. 23(10), 509-515 (2012).
61. Shah PK. Atherosclerosis: targeting endogenous apo A-I-a new approach for raising HDL. Nat. Rev. Cardiol. 8(4), 187-188 (2011).
62. Corton M, Botella-Carretero JI, Benguria A et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92(1), 328-337 (2007).
63. Valkenburg O, Steegers-Theunissen RP, Smedts HP et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J. Clin. Endocrinol. Metab. 93(2), 470-476 (2008).
64. Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin. Endocrinol. (Oxf.) 41(4), 463-471 (1994).
65. Legro RS, Blanche P, Krauss RM, Lobo RA. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil. Steril. 72(6), 990-995 (1999).
66. Yang F, Linehan LA, Friedrichs WE, Lalley PA, Sakaguchi AY, Bowman BH. Characterization of the mouse haptoglobin gene. Genomics 18(2), 374-380 (1993).
67. Alvarez-Blasco F, Martinez-Garcia MA, Luque-Ramirez M, Parraza N, San Millan JL, Escobar-Morreale HF. Role of haptoglobin in polycystic ovary syndrome (PCOS), obesity and disorders of glucose tolerance in premenopausal women. PLoS ONE 4(5), e5606 (2009).
68. Karakurt F, Gumus, II, Bavbek N et al. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecol. Endocrinol. 24(9), 491-497 (2008).
69. Manneras-Holm L, Baghaei F, Holm G et al. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 96(4), 1068-1076 (2011).
70. Gonzalez F, Kirwan JP, Rote NS, Minium J. Elevated circulating levels of tissue factor in polycystic ovary syndrome. Clin. Appl. Thromb. Hemost. 19(1), 66-72 (2012).
71. Lindholm A, Bixo M, Eliasson M et al. Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gynecol. Endocrinol. 26(10), 743-748 (2012).
72. Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J. Clin. Endocrinol. Metab. 87(8), 3871-3875 (2002).
73. Fan L, Ling J, Ma X, Cui YG, Liu JY. Involvement of HSP10 during the ovarian follicular development of polycystic ovary syndrome: Study in both human ovaries and cultured mouse follicles. Gynecol. Endocrinol. 25(6), 392-397 (2009).
74. Rayner K, Chen YX, Siebert T, O'Brien ER. Heat shock protein 27: clue to understanding estrogen-mediated atheroprotection? Trends Cardiovasc. Med. 20(2), 54-58 (2010).
75. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil. Steril. 95(3), 1048-1058 e1041-e1042 (2011).